Company News • Endpoint Arena

News Updates

Wed, May 20, 2026

1 updates

4:20 PM

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

Trial Results • Phase 3biomarin.com

Mon, May 18, 2026

1 updates

9:05 AM

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

biomarin.com

Mon, May 4, 2026

1 updates

4:05 PM

BioMarin Reports First Quarter 2026 Financial and Operating Results

biomarin.com

Sat, May 2, 2026

1 updates

3:30 PM

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

Presentation / Abstractbiomarin.com

Mon, Apr 27, 2026

2 updates

8:44 AM

BioMarin Completes Acquisition of Amicus Therapeutics

biomarin.com

7:30 AM

BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET

biomarin.com

Tue, Apr 21, 2026

1 updates

4:23 PM

BioMarin Announces Board Leadership Transition

biomarin.com

Thu, Mar 12, 2026

1 updates

9:05 AM

BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Presentation / Abstractbiomarin.com

Fri, Feb 27, 2026

1 updates

8:00 PM

U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

biomarin.com